基于BTLA、Treg及其表面标志物FoxP3观察新风胶囊对佐剂关节炎大鼠肺功能的影响

Study of Xinfeng Capsule on the pulmonary function based on BTLA,Tregs and surface markers FoxP3 in the rats with adjuvant arthritis

目的:观察新风胶囊对佐剂关节炎大鼠肺功能,B、T淋巴细胞衰减因子(BTLA),调节性T细胞(Treg)及叉头状转录因子P3(FoxP3)的影响。方法:将60只大鼠随机均分为正常组、模型组、雷公藤组和新风胶囊组,每组15只。除正常组外,其余各组大鼠右后足跖皮内注射弗氏完全佐剂0.1mL致炎。致炎后19d给药,正常组、模型组均给予0.9%氯化钠溶液,治疗组大鼠分别给予新风胶囊(2.4g/kg)、雷公藤多苷片(10mg/kg),1次/d,连续给药30d。观察各组大鼠足跖肿胀度、关节炎指数,流式细胞术检测外周血BTLA、Treg,免疫印迹检测滑膜、肺组织BTLA、FoxP3蛋白表达。结果:与正常组比较,模型组大鼠足跖肿胀度、关节炎指数升高,肺功能降低(P<0.05,P<0.01);外周血BTLA、Treg及滑膜、肺组织BTLA、FoxP3表达降低(P<0.05,P<0.01)。与模型组比较,新风胶囊组足跖肿胀度、关节炎指数降低,肺功能参数、BTLA、Treg、FoxP3升高(P<0.05,P<0.01),并在FEF75、CD4+CD25+FoxP3+Treg及肺组织FoxP3改善方面优于雷公藤组(P<0.05)。结论:新风胶囊可能是通过上调BTLA、Treg、FoxP3表达,减少炎性介质对肺组织的刺激而改善肺功能。

Objective： To observe the impact of Xinfeng Capsule on pulmonary function, B and T lymphocytes attenuator （BTLA）, regulatory T cells （Treg） and FoxP3 in the rat model of adjuvant arthritis. Methods： 60 rats were randomly divided into normal group, model group, tripterygium group and Xinfeng Capsule group. Except for the normal group, the adjuvant was induced in all rats by intracutaneous injection of 0.1 mL Freund＇s complete adjuvant in the right paw. On the 19th day after modeling, the normal and model groups were given physiological saline, while the tripterygium group and Xinfeng Capsule groups were given tfipterygium glycosides tablet （10mg/kg） and Xinfeng Capsule （2.4g/kg）, once dally for 30 days, respectively. Changes in paw swelling, the arthritis index, levels of BTLA, Treg in peripheral blood were observed by flow cytometry, the expressions of BTLA, FoxP3 in synovial and lung tissue were detected by Western blot. Results： Compared with the normal group, the paw swelling, arthritis index increased, and pulmonary function parameter, BTLA, Treg in peripheral blood, and BTLA, FoxP3 in synovial and lung tissue decreased significantly in the model group （P〈0.05, P〈0.01）. The paw swelling, arthritis index were lower, and pulmonary function parameter, Treg, BTLA, FoxP3 were higher in Xinfeng Capsule group than those in the model group （P〈0.05, P〈0.01）. Xinfeng capsule group was also much better than tripterygium group in improving pulmonary function, Treg, BTLA, FoxP3 （P〈0.05）. Conclusion： Xinfeng Capsule can improve pulmonary function by upregulating the levels of, BTLA, Tregs and FoxP3, and reducing inflammatory mediators.